Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for PD-L1-high gastric cancer, drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Two assays with different thresholds leave patients near the cut-off in an uncertain position.
Most patients still progress within a year on chemo-immunotherapy.
How to combine PD-1 blockade with claudin 18.2 or HER2 therapy when targets overlap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
EFS HR 0.
A milestone in how this cancer is treated.
OS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.